Where does Zhongshan Hospital, Fudan University rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Zhongshan Hospital, Fudan University ranks #44,247 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Zhongshan Hospital, Fudan University hold?

Zhongshan Hospital, Fudan University holds 6 US utility patents granted between 2020 and 2024, spanning 10 technology areas.

What is Zhongshan Hospital, Fudan University's Innovation Score?

Zhongshan Hospital, Fudan University has an Innovation Score of 37.7 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Zhongshan Hospital, Fudan University focus on?

Zhongshan Hospital, Fudan University's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 3 patents, ranking #4,499 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Zhongshan Hospital, Fudan University's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Zhongshan Hospital, Fudan University.

What does claim depth mean for Zhongshan Hospital, Fudan University's patents?

Zhongshan Hospital, Fudan University's patents average 10.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Zhongshan Hospital, Fudan University patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Zhongshan Hospital, Fudan University

USPTO PatentsView assignee record - 6 granted patents across 10 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Zhongshan ranks #44,247 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 10 technology areas.

#44,247
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.7/100): 10.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44247 · Foreign Corporation #44,247 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #44,247/49,997
PHOTO-FINISH Zhejiang Raytheon…
CPC-FOCUS A61P · 10 areas
INNOV-THIN 37.7/100
CLAIMS-PAR 10.8 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2024 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Zhejiang Raytheon Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Zhongshan’s 37.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (18%) Velocity 13.3 pts (35%) Breadth 11.2 pts (30%) Claim depth 6.5 pts (17%)

Qualcomm Incorporated · highest

85
Zhongshan Hospital… · this assignee

38
3D Lighting… · lowest

7

What this shows Zhongshan's Innovation Score is 37.7/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Zhongshan?

Each dot is one of Zhongshan’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Zhongshan’s own 10.8 claims/patent is at or below the 12.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Zhongshan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Zhongshan's grants concentrate

Zhongshan Hospital, Fudan University is a focused PatentsView assignee: 10 CPC subclasses with 50% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2023. By volume, Zhongshan sits between Zhejiang Raytheon Technology Co., Ltd. and ZIN Technologies, Inc..

Zhongshan's three-year grant acceleration

Zhongshan Hospital, Fudan University shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Zhejiang Raytheon…

6
Zhejiang Research…

6
Zhejiang Sanou Ma…

6
Zhejiang Xinsheng…

6
Zhongshan Xiaolan…

6
Zhuhai Fast Image…

6
Zignal Labs

6
ZIN

6
Zhongshan Hospita… ◀

6

What this shows Zhongshan holds 6 patents at rank #44,190, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Zhongshan

By rank, the assignees closest to #44,190 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Zhongshan's primary technology class.

Zhongshan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Zhongshan Hospital, Fudan University patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	33.3%
2022	2	33.3%
2023	1	16.7%
2024	1	16.7%

Which technologies does Zhongshan Hospital, Fudan University patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

A61B - DIAGNOSIS; SURGERY; Identification 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C07K - Peptides 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Zhongshan Hospital, Fudan University's patent record in context - here's where to go next.

Zhongshan Hospital, Fudan University's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 50% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #44,247 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Zhongshan Hospital, Fudan University against Zhejiang Raytheon Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.